{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:48:33Z","timestamp":1792633713968,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamacardio.2019.0886","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T13:15:44Z","timestamp":1558530944000},"page":"613","source":"Crossref","is-referenced-by-count":98,"title":["Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease"],"prefix":"10.1001","volume":"4","author":[{"given":"Sabina A.","family":"Murphy","sequence":"first","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Masschusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Ullev\u00e5l and Medical Faculty, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew A.","family":"Gaciong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ceska","sequence":"additional","affiliation":[{"name":"Center for Preventive Cardiology, 3rd Internal Medicine Clinic, University General Hospital and Charles University 1st Medical Faculty, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat V.","family":"Ezhov","sequence":"additional","affiliation":[{"name":"National Cardiology Research Center, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Birmingham City and Sandwell Hospitals and the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalman","family":"Toth","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University of Pecs, Medical School, Pecs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti J.","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Folkh\u00e4lsan Research Center, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungah","family":"Im","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Masschusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Masschusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimon","family":"Honarpour","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Masschusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[{"name":"Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"Imperial College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Masschusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"25","key":"hoi190016r1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","article-title":"Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.","volume":"54","author":"Murphy","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"hoi190016r2","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.jacc.2009.08.035","article-title":"Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.","volume":"54","author":"Tikkanen","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi190016r3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial.","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"hoi190016r4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"hoi190016r5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"hoi190016r6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"9493","key":"hoi190016r7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9753","key":"hoi190016r8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"hoi190016r9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi190016r10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"14","key":"hoi190016r11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"hoi190016r12","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"hoi190016r13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi190016r14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjcard.2009.09.025","article-title":"Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).","volume":"105","author":"LaRosa","year":"2010","journal-title":"Am J Cardiol"},{"issue":"29","key":"hoi190016r15","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/7\/613\/17729246\/jamacardiology_murphy_2019_oi_190016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T11:03:00Z","timestamp":1563361380000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.0886"}},"subtitle":["A Prespecified Analysis From the FOURIER Trial"],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.0886","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}